GHK-Cu
GHK-Cu is a human copper-binding tripeptide (Gly-His-Lys chelated to Cu2+) that Pickart 2018 characterized as regulating roughly 4,192 human genes, including DNA repair, antioxidant, and tissue-remodeling pathways. Finkey 2005 (67-subject facial RCT) and Abdulghani 1998 (facial biopsy pilot) show topical collagen/elastin stimulation; systemic injection dosing remains community-derived with zero human RCTs.
GHK-Cu scored 6.9 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Peptide → Growth / Repair Peptide.
What It Is
GHK-Cu is the copper-chelated form of glycyl-L-histidyl-L-lysine, a naturally occurring human tripeptide discovered by Loren Pickart in 1973. It circulates in human plasma at approximately 200 ng/mL in young adults and declines roughly 60% by age 60, a gradient Pickart's lab and the Linus Pauling Institute have characterized as a candidate driver of age-associated regenerative decline.
Type: Peptide (copper-binding tripeptide glycyl-L-histidyl-L-lysine; gray-market cosmeceutical and research peptide).
Current status: Legal and well-established as a cosmetic ingredient worldwide (CIR-reviewed, EU CosIng-listed without restriction). Topical formulations are mature and widely available from NIOD, The Ordinary, Neova, Osmosis, and specialty apothecaries. Transdermal patches (LifeWave X39) are commercially available with company-funded pharmacokinetic data only. Injectable forms are not approved in any jurisdiction and are sold via research-chemical vendors, compounding pharmacies in narrow legal contexts, and the gray-market peptide community. Nick has personally used GHK-Cu across topical and patch routes, preferring non-injection delivery for longevity, stem cell, and DNA repair signaling.
The biology runs on controlled copper hand-off. GHK binds Cu2+ with extraordinary affinity (dissociation constant near 10^-16) and then delivers copper to a roster of downstream enzymes including lysyl oxidase (collagen and elastin cross-linking), superoxide dismutase (SOD, antioxidant defense), and cytochrome c oxidase (mitochondrial electron transport). Three mechanistic layers stack on top of that chaperone role. First, GHK-Cu is a direct superoxide-dismutase mimetic, catalytically reducing superoxide to hydrogen peroxide and sequestering free copper to prevent Fenton-driven hydroxyl radical production. Second, Pickart 2015 Broad Institute Connectivity Map analysis at 1 uM identified ~4,192 human genes whose expression is modulated by GHK, clustered in DNA repair, antioxidant defense, tissue remodeling, and cellular senescence reversal. Third, GHK-Cu upregulates TIMP-1 and TIMP-2 (tissue inhibitors of matrix metalloproteinases), reducing MMP-driven matrix degradation while simultaneously stimulating fibroblast collagen and elastin synthesis (Maquart 1988 Reims group provided the critical independent replication).
Terminology
- GHK: Glycyl-L-histidyl-L-lysine, the human tripeptide sequence. Refers to the apo-peptide before copper binding.
- Cu: Copper in its Cu2+ oxidation state; the essential cofactor chelated by GHK.
- GHK-Cu: The copper-chelated complex with a roughly 1:1 GHK:Cu2+ stoichiometry and the form with documented biological activity.
- SOD: Superoxide dismutase, the antioxidant metalloenzyme family that catalyzes conversion of superoxide to hydrogen peroxide. GHK-Cu is a SOD mimetic.
- DNA repair: The collective enzymatic pathways (base excision, nucleotide excision, double-strand break repair) whose genes Pickart 2015 documented as upregulated by GHK-Cu.
- TIMP-1 / TIMP-2: Tissue inhibitors of matrix metalloproteinases. Upregulated by GHK-Cu, they brake MMP-driven matrix breakdown.
- MMP: Matrix metalloproteinases, the collagenase and gelatinase family that degrades extracellular matrix. Over-activity drives photoaging.
- Fibroblast: The dermal cell that synthesizes collagen, elastin, and ground-substance glycosaminoglycans. GHK-Cu stimulates fibroblast production of all three (Maquart 1988).
- Keratinocyte: The primary skin epidermal cell. GHK-Cu supports keratinocyte migration, barrier repair, and post-wound epithelialization.
- Collagen type I / III: The major structural collagen isoforms in skin and wound beds. GHK-Cu stimulates both, with relative type III upregulation favoring fetal-pattern repair.
- Stem cell: Undifferentiated progenitor cell. GHK-Cu upregulates stem-cell markers (integrin-alpha-6, p63) in keratinocyte niches and modulates mesenchymal stem cell migration in vitro.
- TRT: Testosterone replacement therapy. Referenced here as a common co-protocol context; no direct GHK-Cu interaction known.
- Patches: Transdermal photobiomodulation or peptide-loaded patches (LifeWave X39 is the most widely used GHK-Cu patch), claimed to elevate endogenous GHK via light-mediated signaling.
- Microneedling: Controlled fractional dermal injury using fine needles, commonly paired with post-procedure GHK-Cu serum to exploit the disrupted stratum corneum and accelerate recovery.
- Iontophoresis: Electrical delivery of charged molecules through skin. Amplifies GHK-Cu topical delivery versus passive diffusion.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Topical (serum 0.05-2% GHK-Cu) | aqueous serum or cream | 0.5-3% cream 1-2x/day | 0.05-2% serum daily; stacked with Matrixyl, retinol, niacinamide |
| Topical patch (transdermal) | LifeWave X39 patch | ~15-20 mg patch daily; ~40% serum increase per company-funded PK study | daily patch placement (neck/spine) |
| Subcutaneous injection | lyophilized powder reconstituted in bacteriostatic water | none (zero human injection RCTs) | 1-5 mg/day SC; most commonly 1-2 mg/day |
| Intranasal | reconstituted peptide spray | none | 0.2-0.5 mg/day |
Protocols
Skin and hair (daily topical, default) Clinical
- Dose
- 0.5-3% topical serum or cream
- Frequency
- 1-2x/day
- Duration
- 8-12 weeks for wrinkle/firmness endpoints
RCT-supported for wrinkle reduction, post-procedure erythema, hair density. Stack with Matrixyl, retinol (alternate nights to avoid pH conflict), niacinamide, and collagen peptides.
Systemic longevity (injection, community) Anecdotal
- Dose
- 1-2 mg SC
- Frequency
- daily
- Duration
- 30 days on / 30 days off, cycled
Zero human RCTs. Popular in peptide-stack community for longevity, stem cell activation, DNA repair. Never combine with copper disulfiram therapy. Avoid in Wilson's disease.
Post-microneedling / post-procedure Mixed
- Dose
- 2-3% GHK-Cu serum applied immediately post-procedure
- Frequency
- 1-2x/day for 5-7 days
- Duration
- 5-7 days
Community and aesthetic-practitioner protocol. Drives deeper penetration via disrupted stratum corneum. Iontophoresis amplifies delivery further.
Hair loss (scalp topical) Mixed
- Dose
- 0.5-1% GHK-Cu topical
- Frequency
- daily scalp application
- Duration
- 3-6 months
Pickart 2018 hair-follicle review supports follicular size increase and growth-phase induction. Most effective paired with minoxidil or microneedling.
How this score is calculated →
Upside (2.18 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.5 | 0.875 | |
| Breadth of Benefits | 15% | 3.5 | 0.525 | |
| Evidence Quality | 25% | 3.0 | 0.750 | |
| Speed of Onset | 10% | 2.5 | 0.250 | |
| Durability | 10% | 2.5 | 0.250 | |
| Bioindividuality Upside | 15% | 3.5 | 0.525 | |
| Total | 3.175 |
Upside Rationale
Efficacy (3.5/5.0). Topical GHK-Cu has RCT-scale human endpoint data. Finkey 2005 67-subject facial RCT on photoaged skin reported Cohen's d roughly 0.3 to 0.6 on wrinkle depth, firmness, and skin thickness endpoints. Abdulghani 1998 facial biopsy pilot demonstrated collagen and elastin increase under copper-peptide cream versus vitamin C and melatonin comparators. Mulder 1994 diabetic foot ulcer RCT reported 98.5% closure in the GHK-Cu arm versus 60.8% in the control arm, a clinically meaningful delta. The systemic injection route has zero human RCTs and scores on mechanism plus anecdote only. Score reflects a weighted average: strong topical demonstration plus weak-but-plausible systemic signal. Patches deliver sustained low-dose exposure with longer effective half-life than injection but rely on company-funded PK data.
Breadth of Benefits (3.5/5.0). Skin regeneration, wound healing, hair-follicle stimulation, scar reduction, post-procedure erythema recovery, DNA repair gene signaling, stem-cell marker upregulation, nerve-outgrowth support in preclinical models, and anti-fibrotic TGF-beta modulation. Pickart 2015 identified ~4,192 regulated genes, which is a multi-system signal across integumentary, immune, nervous, and connective-tissue domains. The signal weakens outside skin and wound beds: cardiovascular, metabolic, and respiratory benefits are mostly mechanistic inferences rather than demonstrated human endpoints.
Evidence Quality (3.0/5.0). Fifty-plus years of published research since Pickart 1973. Several human topical RCTs (Finkey 2005, Leyden 2002, Abdulghani 1998, Mulder 1994) but a meaningful share is Procyte/Neova/PhotoMedex-funded cosmeceutical work with the Pickart inventor bias flag. Independent in-vitro fibroblast replication by the Maquart Reims group is the critical non-Pickart validation. CIR cosmetic safety review, EU CosIng listing, and decades of cosmetic-grade exposure provide strong real-world safety data. Per v0.5 evidence-integrity rules, a −0.5 industry-funding penalty applies because the strongest RCTs and Pickart's later reviews carry a non-independent funding trail, but not −1.0 because independent replication exists (Maquart) and there is no burial signal. Systemic injection evidence remains tier-5/6 (mechanistic plus anecdotal).
Speed of Onset (2.5/5.0). Hydration and barrier improvements are reported within 1 to 2 weeks of topical use. Wrinkle depth and firmness endpoints reach significance between weeks 4 and 8 in the Finkey and Leyden data, peaking around 12 weeks. Wound granulation in the Mulder diabetic foot ulcer trial was observed within days of topical application. Systemic injection protocols produce subtle, often sub-perceptual changes over months, consistent with a gene-expression-driven rather than receptor-binding-driven mechanism. GHK-Cu is not a fast-felt molecule in the way caffeine, creatine loading, or GLP-1 agonists are.
Durability (2.5/5.0). Use-dependent. Topical benefits reverse gradually over weeks of discontinuation as collagen turnover resumes baseline. No published human washout data for injection. The mechanism is continuous stimulation rather than a one-time reset, so sustained effect requires sustained use. Unlike senolytics or epigenetic reprogrammers with durable post-dose effects, GHK-Cu behaves as a maintenance signal: benefits accrue on exposure and fade on withdrawal.
Bioindividuality Upside (3.5/5.0). The clean responder profile is photoaged and older skin, because baseline endogenous GHK is lowest where the delta to youthful levels is widest. Pickart data suggests the largest collagen-depleted baselines (age 40+) show the biggest deltas on topical endpoints. Post-menopausal women with thinning skin and collagen loss are another strong responder cohort. Younger users with intact endogenous GHK and high baseline collagen see proportionally smaller wrinkle-endpoint changes, although wound-healing and post-procedure-recovery benefits appear preserved across ages. Hair responders are over-represented among individuals with early androgenic thinning who have intact follicular architecture; GHK-Cu does not regrow hair from fully miniaturized follicles.
Downside (0.93 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.0 | 0.600 | |
| Side Effect Profile | 15% | 2.0 | 0.300 | |
| Financial Cost | 5% | 1.5 | 0.075 | |
| Time/Effort Burden | 5% | 2.0 | 0.100 | |
| Opportunity Cost | 5% | 2.0 | 0.100 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.700 | |||
| Harm subtotal × 1.4 | 1.995 | |||
| Opportunity subtotal × 1.0 | 0.275 | |||
| Combined downside | 2.270 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.930 |
Downside Rationale
Safety Risk (2.0/5.0). Topical GHK-Cu is exceptionally safe with CIR review, EU CosIng clearance, and decades of cosmeceutical-grade exposure without meaningful AE clustering. Injectable GHK-Cu carries theoretical concerns that have not materialized into catastrophic events. Copper accumulation is an absolute contraindication in Wilson's disease (where baseline copper metabolism is defective), and the pro-angiogenic gene-expression signature that favors wound healing also theoretically favors tumor angiogenesis, so systemic use is cautioned in active malignancy. Per v0.5 catastrophic-floor rules the score does not trigger the 4.0 floor because no intrinsic life-threatening AE has been documented at cosmeceutical or community-injection doses. Gray-market injection carries extrinsic supply-chain risk (endotoxin, purity, copper-dose variance) that is tracked in the Verdict rather than inflating this intrinsic score.
Side Effect Profile (2.0/5.0). Topical route: rare contact sensitization in ~1-2% of users, occasional mild erythema on first application, and rare bluish-green discoloration at high concentrations (a visible sign of copper deposition that resolves with discontinuation). Injectable route: injection-site reactions (erythema, mild induration), rare transient metallic taste, and occasional bluish-green tint at the injection site in long-term users. Patches are generally well-tolerated; adhesive-site irritation is the main complaint. No systemic toxicity at cosmetic or community-injection doses. The side-effect burden is lower than most peptide-class interventions and markedly lower than retinoids, BPC-157 (which carries injection-site variability), or systemic GLP-1 agonists.
Financial Cost (1.5/5.0). Topical GHK-Cu formulations run $30-100/month depending on brand (The Ordinary at the budget end, NIOD and Osmosis at the premium end, Neova and specialty apothecaries in between). Peptide-grade injectable vials run $60-150/month from compounding pharmacies and the gray-market vendor network. LifeWave X39 patches run roughly $100-150/month at retail. Per v0.5 accessible-channel cost rules, scored at the topical and generic peptide-vial range that a motivated user actually pays, well below the $200/month penalty threshold.
Time/Effort Burden (2.0/5.0). Daily topical application takes under one minute and stacks with existing AM/PM skincare routines. Patches are change-once-daily with similar friction to a vitamin pill. Injection protocol requires reconstitution with bacteriostatic water, insulin-syringe dosing, rotation of SC injection sites, and proper sterile technique: a modest but meaningful burden for injection-averse users. Post-microneedling and iontophoresis-amplified delivery add a further 10-15 minutes to the effort envelope on treatment days. Total daily time commitment typically runs under 5 minutes for topical/patch routes and 10-15 minutes for injection days, a low-to-moderate friction level relative to multi-peptide stacks but higher than a swallow-a-capsule intervention.
Opportunity Cost (2.0/5.0). GHK-Cu stacks rather than displaces. It complements tretinoin, Matrixyl, niacinamide, collagen peptides, BPC-157, and general skincare protocols without competing for the same mechanism. The main trade-off is attention-budget: peptide stacks can sprawl, and GHK-Cu injection is occasionally used as a substitute for a more systematic sleep-and-training-quality foundation, which is the classic biohacker mistake. Per v0.5 audience-vs-indication rules, scored for the aesthetically-and-longevity-motivated user who has already solved sleep, training, and diet; for users who haven't, GHK-Cu is a distraction rather than a dimension penalty.
Dependency/Withdrawal (1.0/5.0). None demonstrated across any route. No receptor down-regulation, no HPA-axis involvement, no tolerance development, and no withdrawal syndrome documented in cosmetic, patch, or injection populations across fifty-plus years of human use (Pickart 1973 to 2018 reviews). Stopping GHK-Cu produces no craving, no rebound breakout, no withdrawal-linked symptoms. Unlike corticosteroids that suppress endogenous cortisol or GLP-1 agonists that trigger weight-regain on cessation, GHK-Cu behaves as pure signaling augmentation: when exogenous supply stops, the system reverts to whatever endogenous GHK level age and physiology produce. Per v0.5 dependency-vs-addiction framework, this is the substrate-class floor and earns the full 1.0 score. Returning to baseline collagen-turnover rates is the only reversion, unfolding over weeks rather than as an abrupt withdrawal event.
Reversibility (1.5/5.0). Fully reversible. Topical and patch effects on skin firmness, hydration, and barrier integrity fade over weeks to months of discontinuation as collagen and elastin turnover resume baseline. No irreversible structural change has been documented. The modest bump above the 1.0 floor reflects that collagen gained from chronic topical use is not permanently retained once dosing stops, rather than any true irreversibility.
Verdict
Best for: Topical use on photoaged skin (40+), post-procedure erythema recovery (post-microneedling, post-laser, post-chemical-peel), hair density adjunct for early androgenic thinning with intact follicles, and diabetic or chronic wound healing. Patches for sustained low-dose delivery in longevity-oriented stacks. Peptide-community users pursuing DNA repair and stem-cell gene-expression signaling who accept the zero-RCT state of systemic injection evidence and source carefully. Pair with Matrixyl, niacinamide, retinol (alternate nights to avoid pH conflict), oral collagen peptides, and post-microneedling or iontophoresis delivery for amplified effect.
Avoid if: Wilson's disease (absolute contraindication due to copper-accumulation risk). History of copper toxicity or neurological copper disorders. Active malignancy (theoretical angiogenesis concern for systemic delivery; topical near cutaneous malignancy also contraindicated). Pregnancy or lactation (data insufficient). Anyone expecting oral capsules to work systemically (the tripeptide is GI-degraded). Anyone sourcing gray-market injectable product without third-party certificates of analysis (Janoshik or equivalent): the molecule is safe, the supply chain is not. Anyone expecting felt subjective effects on the timescale of caffeine or creatine; GHK-Cu is a mechanism-trust intervention on a weeks-to-months timescale.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ✅ Skin / Beauty | 9.0 | RCT-proven wrinkle reduction; stimulates collagen, elastin, and glycosaminoglycan synthesis |
| ✅ Wound Healing | 8.0 | Accelerates wound contraction and epithelialization; attracts immune cells to wound site |
| 💪 Recovery / Repair | 7.0 | Tissue remodeling via collagen synthesis, angiogenesis, and anti-inflammatory activity |
| 💪 Neuroprotection | 7.0 | Modulates gene expression of antioxidant enzymes SOD and GPx in neural tissue |
| 💪 Anti-Inflammatory | 7.0 | Suppresses TGF-beta-driven fibrosis and reduces IL-6, TNF-alpha signaling |
| 👍 Stem Cell Support | 6.5 | Upregulates stem cell markers and increases mesenchymal stem cell activity |
| 👍 Antioxidant / Oxidative Stress | 6.5 | Potent SOD and GPx inducer; sequesters free copper to prevent Fenton reactions |
| 👍 Longevity / Lifespan | 6.5 | Resets 50+ gene expressions toward youthful patterns; Linus Pauling Institute research |
| 👍 Nerve Regeneration | 6.0 | Promotes nerve outgrowth and Schwann cell migration in preclinical models |
| 👍 Geriatric / Aging Population | 6.0 | Naturally declines with age; supplementation restores youthful gene expression |
| 👍 Injury Recovery | 6.0 | Broad tissue repair via collagen remodeling and angiogenesis |
| 👍 Healthspan | 6.0 | Multi-system anti-aging gene modulation across 50+ pathways |
| 👍 Telomere / DNA Repair | 6.0 | Upregulates DNA repair genes; some evidence for telomerase support |
| ⚖️ Respiratory | 5.5 | Anti-fibrotic properties relevant to lung tissue; COPD preclinical data |
| ○ Cardiovascular | 4.5 | Cardioprotective gene modulation; anti-fibrotic in cardiac tissue |
| ○ Gut Health / Microbiome | 4.5 | Anti-inflammatory and tissue repair properties extend to GI mucosa |
| ○ Hair / Nail Health | 4.5 | Increases hair follicle size and stimulates growth phase; copper peptide hair products |
| ○ Cellular Senescence | 4.5 | Reverses fibroblast senescence markers; restores youthful gene expression |
| ○ Immune Function | 4.0 | Modulates immune cell recruitment and inflammatory signaling |
| ○ Cognition / Focus | 4.0 | Neuroprotective gene modulation may support cognitive function |
| ○ Bone / Joint Health | 4.0 | Stimulates osteoblast activity and collagen formation in bone |
| ○ Acute Pain Relief | 4.0 | Anti-inflammatory action reduces pain at tissue level |
| ○ Neuroplasticity | 4.0 | Nerve growth factor interactions support synaptic remodeling |
| ○ Anxiety | 4.0 | GABAergic gene modulation in preclinical data |
| ○ Memory | 4.0 | Neuroprotective effects may preserve hippocampal function |
| ○ Chronic Pain Management | 4.0 | Anti-fibrotic and tissue repair address chronic pain root causes |
| ○ Traumatic Brain Injury | 4.0 | Neuroprotective and anti-inflammatory; neural repair support |
| ○ Mood / Emotional Regulation | 3.5 | Indirect via neuroprotection and anti-inflammatory pathways |
| ○ Stress / Resilience | 3.0 | Antioxidant gene upregulation protects against oxidative stress |
| ○ Depression | 3.0 | Neuroprotective; limited direct antidepressant evidence |
| ○ Muscle Growth / Hypertrophy | 3.0 | Collagen support for connective tissue; not a direct anabolic |
| ○ Energy / Fatigue | 3.0 | Mitochondrial gene support; indirect energy benefit |
| ○ Mitochondrial | 3.0 | Upregulates mitochondrial gene expression in aging models |
| ○ Autophagy | 3.0 | Gene modulation may support cellular cleanup pathways |
Frequently Asked Questions
What is GHK-Cu and how does copper-peptide binding actually work?
GHK-Cu is the copper-chelated form of the human tripeptide glycyl-L-histidyl-L-lysine (GHK), an endogenous copper carrier Pickart first isolated from human plasma in 1973 (Nature New Biology 243:85). Its biology is driven by controlled Cu2+ hand-off: GHK binds copper with a dissociation constant around 10 to the -16, then delivers copper to enzymes like lysyl oxidase, superoxide dismutase (SOD), and cytochrome c oxidase. Pickart 2015 (Broad Institute Connectivity Map analysis at 1 uM) identified ~4,192 human genes whose expression is modulated by GHK, clustered in DNA repair, antioxidant defense, and tissue remodeling.
What is the difference between GHK-Cu topical, injection, and patches?
The routes are not interchangeable and have fundamentally different evidence bases. Topical cream at 0.5-3% is the RCT-anchored path (Finkey 2005 67-subject facial RCT, Leyden 2002, Abdulghani 1998, Mulder 1994 diabetic ulcers) and targets skin, hair, and post-procedure endpoints. Subcutaneous injection at 1-2 mg/day has zero human RCTs and is used by the peptide community for systemic longevity, stem cell activation, and DNA repair signaling. LifeWave X39 photobiomodulation patches claim ~40% serum GHK elevation but the supporting PK data is company-funded only. Topical is the strongest evidence path; injection is anecdotal; patches are intermediate with a conflict-of-interest flag.
What is the evidence for GHK-Cu on skin and hair?
The topical skin evidence is solid and replicated. Finkey 2005 ran a 67-subject facial RCT showing firmness, thickness, and wrinkle depth improvement. Abdulghani 1998 used facial biopsies to demonstrate collagen and elastin increase under copper-peptide cream versus vitamin C and melatonin. Leyden 2002 replicated on photoaged skin. For hair, Pickart 2018 (Int J Mol Sci 19:1987) reviewed follicle-size increase and growth-phase induction. Independent in-vitro replication by Maquart 1988 confirms fibroblast collagen stimulation is a real mechanism, not just Pickart-lab-only data.
Does GHK-Cu actually work for systemic longevity and DNA repair?
The systemic longevity claim rests on mechanism, not human RCTs. Pickart 2015 Connectivity Map analysis shows GHK modulates ~4,192 human genes at 1 uM, with statistically significant clustering in DNA repair, antioxidant defense, and cellular senescence reversal pathways. Pickart 2012 earlier reviewed UV-damage protection and fibroblast senescence reversal. Zero human injection RCTs exist, so the 1-2 mg/day SC protocol is a mechanistic bet, not a demonstrated endpoint. The evidence is strong at the gene-expression level and weak at the human lifespan-endpoint level.
Does GHK-Cu really activate stem cells?
Preclinical data supports limited stem-cell modulation. GHK-Cu upregulates stem-cell markers including integrin-alpha-6 and p63 in keratinocytes and modulates mesenchymal stem cell migration in vitro. Pickart 2018 collated the preclinical and ex-vivo evidence. No human RCT has demonstrated systemic stem-cell mobilization from GHK-Cu administration. The claim is biologically plausible at the tissue-niche level (skin, hair follicle, wound bed), and more speculative at the systemic stem-cell-activation level.
Is gray-market injectable GHK-Cu safe and how do I source it?
Per v0.5 supply-chain rules, the compound itself is intrinsically safe in topical cosmetic use (CIR-reviewed, EU CosIng-listed without restriction). The risk is extrinsic: gray-market injectable peptides carry copper-dose variance, endotoxin, and purity risk, none of which are properties of the GHK-Cu molecule. Require third-party analytical certificates of analysis (Janoshik, independent mass-spec peptide testing) before using injectable product. Cosmetic-grade topicals from established brands (NIOD, The Ordinary, Neova, Osmosis) are mature and regulated. Injection sourcing should default to compounding pharmacies where legal, not anonymous research-chemical vendors.
Can I stack GHK-Cu with Matrixyl, retinol, and collagen supplements?
Yes. GHK-Cu stacks cleanly with Matrixyl (palmitoyl pentapeptide-4) for synergistic collagen stimulation, with niacinamide for barrier support, and with oral collagen peptides as a systemic substrate for new matrix synthesis. Retinol and GHK-Cu are best applied on alternate nights to avoid pH conflict (GHK-Cu is pH-sensitive). GHK-Cu is frequently stacked with BPC-157 in peptide protocols for wound healing and soft-tissue recovery. Avoid simultaneous use with aggressive exfoliating acids in the same application window.
Who should avoid GHK-Cu?
Avoid GHK-Cu in Wilson's disease (absolute contraindication due to copper-accumulation risk) and in documented copper toxicity or neurological copper disorders. Use caution with active malignancy given the pro-angiogenic gene-expression signature (pro-angiogenesis is wanted for wound healing but not for tumor growth); topical use near active skin cancers is contraindicated. Pregnancy and lactation data are insufficient. Do not expect oral capsule GHK-Cu to work systemically: the tripeptide is GI-degraded and requires topical, transdermal, or injection delivery.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension shifts | New score |
|---|---|---|
| Independent dermatology RCT replicates d>0.6 on firmness | Efficacy 3.5 to 4.0, Evidence 3.0 to 3.5 | 7.3 / 10 (💪 Strong recommend) |
| First human injection PK study shows safe systemic exposure | Evidence 3.0 to 3.5, Bioindividuality 3.5 to 4.0 | 7.2 / 10 (💪 Strong recommend) |
| Case report cluster of copper neurotoxicity from chronic injectable use | Safety 2.0 to 3.5 | 5.9 / 10 (👍 Worth trying) |
| Randomized hair-regrowth trial confirms density endpoint vs minoxidil | Efficacy 3.5 to 3.8, Breadth 3.5 to 3.8 | 7.2 / 10 (💪 Strong recommend) |
| Independent lab fails to replicate Maquart fibroblast collagen result | Evidence 3.0 to 2.3, Efficacy 3.5 to 3.0 | 6.1 / 10 (👍 Worth trying) |
Key Evidence Sources
- Pickart L, Thaler MM. 1973. Tripeptide in human serum which prolongs survival of normal liver cells. Nature New Biology 243:85-87.. Foundational discovery paper
- Maquart FX, et al. 1988. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.. Independent replication of fibroblast collagen stimulation (Reims group)
- Pickart L. 2015. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Oxid Med Cell Longev 2015:648108.. Broad Institute Connectivity Map analysis identifying ~4,192 human genes regulated at 1 uM
- Pickart L, Margolina A. 2018. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci 19(7):1987.. Comprehensive regenerative actions update including hair-follicle, DNA-repair, and antioxidant pathways
- Pickart L. 2012. Gene expression modulation review. Oxid Med Cell Longev 2012.. Earlier gene-expression modulation review
- Schagen SK. 2017. Topical peptide treatments with effective anti-aging results. Skinmed review.. Tripeptide cosmeceutical efficacy review
- Finkey MB, Appa Y, Bhandarkar S. 2005. Copper Peptide and Skin. In: Elsner P, Maibach HI eds. Cosmeceuticals and Active Cosmetics. CRC Press.. 67-subject facial RCT on photoaged skin (firmness, wrinkle depth)
- Mulder GD, et al. 1994. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. J Am Acad Dermatol.. 98.5% vs 60.8% wound closure on diabetic foot ulcers
- Abdulghani AA, et al. 1998. Effects of topical creams containing vitamin C, a copper-binding peptide cream, and melatonin compared with tretinoin on the ultrastructure of normal skin. Dis Manage Clin Outcomes.. Facial biopsy pilot showing collagen and elastin increase under copper-peptide cream
- Leyden JJ, et al. 2002. Skin care benefits of copper peptide containing facial cream. American Academy of Dermatology 60th Annual Meeting.. Photoaged skin study supporting topical GHK-Cu firmness and smoothness endpoints
- CIR (Cosmetic Ingredient Review) Expert Panel. Safety assessment of copper tripeptides. Int J Toxicol.. Concluded safe as used in cosmetics
- EU CosIng database entry (Copper Tripeptide-1 / GHK-Cu).. No restrictions on cosmetic use within the EU
Other interventions for Skin & Beauty
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.175 − 0.930 = 1.245
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((1.245 + 7) / 12) × 10 = 6.9 / 10
